173089-24-2Relevant academic research and scientific papers
Novel 4-trifluoromethylthiazole-5-carboxylic acid as acceptor in photosensitized dyes
Iwata, Satoru,Aoyama, Misa,Uchida, Satoshi,Tanaka, Kiyoshi
, p. 1560 - 1562 (2012)
Novel photosensitized dyes containing 4-trifluoromethyl-thiazole-5- carboxylic acid as an acceptor are synthesized. Stilbene-type dyes with this acceptor show high performance as dye-sensitized solar cells. The trifluoromethyl group is assumed to act as a suppressor of electron back-donation from the TiO2 conduction band to the electrolyte and as an accelerator of charge separation in the photoexcited state.
Enhanced ratiometric fluorescent indicators for magnesium based on azoles of the heavier chalcogens
Afzal, Mohammad S.,Pitteloud, Jean-Philippe,Buccella, Daniela
, p. 11358 - 11361 (2014)
Red-shifted fluorescent indicators for magnesium were developed by incorporation of sulfur or selenium in the azole moiety of 'fura' fluorophores. Single atom replacement in the acceptor of these ITC probes affords longer excitation and emission wavelengths as well as greater separation between excitation bands, valuable for ratiometric intracellular Mg2+ imaging. the Partner Organisations 2014.
SULFONAMIDE COMPOUND OR SALT THEREOF
-
Page/Page column 23, (2011/04/25)
[Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP 1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
Heterocycles useful in the treatment of benign prostatic hyperplasia
-
Page column 26, (2010/02/05)
This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
-
, (2008/06/13)
The invention provides compounds of formula I: STR1 wherein A, B, D, X, R1, and R3 have any of the values defined in the specification, as well as N-oxides thereof, S-oxides thereof, pharmaceutically acceptable salts thereof, and in vivo hydrolizable esters and amides thereof, that are useful to relieve pain. The invention also provides pharmaceutical compositions as well as synthetic and therapeutic methods relating to such compounds.
